Here we describe the development and characterization of a novel BET inhibitor UM-002 with brain penetrant properties that reduces GBM cell proliferation in vitro and ex vivo, and alters the proportion of cells within different cell cycle states in vivo. This evidence concerns the gene DNER and glioblastoma.